```html

Zollinger‑Ellison‑type Epigastric Burning

What is Zollinger‑Ellison‑type epigastric burning?

Zollinger‑Ellison‑type epigastric burning describes a severe, gnawing pain or “burn” that is felt in the upper central part of the abdomen (the epigastrium) and is caused by excess gastric acid secretion that is typical of a Zollinger‑Ellison syndrome (ZES)–related ulcer. ZES is a rare neuroendocrine tumor (a gastrinoma) that produces large amounts of gastrin, a hormone that stimulates the stomach to produce acid. The resulting acid overload damages the lining of the stomach and duodenum, causing ulceration and the characteristic burning sensation.

Although the term “Zollinger‑Ellison‑type” is sometimes used by clinicians to describe any epigastric burning that resembles the pain pattern seen in ZES—even when a gastrinoma has not been confirmed—the underlying mechanism remains the same: too much acid in the stomach, leading to irritation of the mucosa.

Understanding this symptom is important because it can signal an underlying condition that may require specific treatment, such as surgery or high‑dose acid‑suppression therapy, and because untreated acid excess can lead to serious complications (bleeding, perforation, or malignant transformation).

Common Causes

The epigastric burning that mimics Zollinger‑Ellison syndrome can be triggered by a variety of disorders that increase gastric acid secretion or compromise the protective mucosal barrier. The most frequent contributors are:

• Zollinger‑Ellison syndrome (gastrinoma) – a rare pancreatic or duodenal neuroendocrine tumor.
• Peptic ulcer disease (PUD) – usually associated with Helicobacter pylori infection or NSAID use.
• Gastric hypersecretion syndromes – such as chronic atrophic gastritis with autoimmune gastritis.
• Gastroesophageal reflux disease (GERD) – reflux of acid into the esophagus can cause a burning sensation that radiates to the epigastrium.
• Medication‑induced hyperacidity – especially long‑term use of corticosteroids, bisphosphonates, or potassium‑sparing diuretics.
• Secretin‑positive tumors – rare duodenal tumors that also stimulate gastrin release.
• Helicobacter pylori infection – stimulates gastrin release and reduces mucosal defenses.
• Chronic NSAID or aspirin consumption – damages the mucosal barrier and can provoke ulcer‑related burning.
• Stress‑related mucosal disease (e.g., severe burns, trauma, ICU patients) – leads to increased acid production and mucosal injury.
• Hyperparathyroidism – calcium excess can increase gastrin release in some patients.

Associated Symptoms

While the burning sensation may be the most noticeable complaint, it is often accompanied by other gastrointestinal or systemic signs that help clinicians narrow the diagnosis:

• Upper abdominal pain that improves or worsens with meals (often worse after eating in ZES).
• Heart‑burn or acid reflux.
• Nausea and occasional vomiting, which may be coffee‑ground or contain blood.
• Loss of appetite and unintended weight loss.
• Frequent burping or belching.
• Dark, tarry stools (melena) indicating upper‑GI bleeding.
• Fatigue or dizziness from anemia caused by chronic blood loss.
• Diarrhea or steatorrhea (fatty stools) in some ZES patients due to rapid gastric emptying.
• Occasional jaundice if a tumor compresses the biliary tree.

When to See a Doctor

Most occasional heart‑burn resolves with lifestyle changes, but the following situations merit prompt medical evaluation because they may indicate a more serious underlying problem:

• Burning pain that persists > 2 weeks despite over‑the‑counter antacids.
• Severe, worsening, or unrelenting pain that wakes you at night.
• Vomiting blood, material that looks like coffee grounds, or passing black, tarry stools.
• Unexplained weight loss > 5 % of body weight in a short period.
• Persistent nausea or vomiting that prevents you from keeping food or fluids down.
• Difficulty swallowing (dysphagia) or a sensation of food “sticking.”
• History of Zollinger‑Ellison syndrome, pancreatic neuroendocrine tumor, or chronic H. pylori infection.

Diagnosis

Diagnosing the cause of Zollinger‑Ellison‑type burning involves a stepwise approach that combines clinical evaluation, laboratory testing, imaging, and sometimes endoscopic procedures.

1. Clinical History & Physical Exam

Doctors will ask about the pattern of pain, medication use, alcohol intake, smoking, family history of ulcers, and prior H. pylori infection or gastric surgery.

2. Laboratory Tests

• Serum gastrin level – markedly elevated (> 1,000 pg/mL) in ZES, especially after a secretin stimulation test.
• Fasting gastric pH – a pH < 2 in the presence of high gastrin strongly suggests a gastrinoma.
• H. pylori testing – stool antigen, urea breath test, or serology.
• Complete blood count (CBC) – to detect anemia from chronic bleeding.
• Comprehensive metabolic panel – assesses electrolyte disturbances from vomiting or diarrhea.

3. Endoscopy (EGD – esophagogastroduodenoscopy)

Allows direct visualization of the esophagus, stomach, and duodenum, identifies ulcerations, and enables biopsy to rule out malignancy or H. pylori infection.

4. Imaging Studies

• CT or MRI of the abdomen – to locate gastrin‑producing tumors, especially in the pancreas or duodenum.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors.
• Ultrasound (endoscopic or transabdominal) – useful for detecting liver metastases.

5. Special Tests

In equivocal cases, a secretin stimulation test is performed: secretin normally suppresses gastrin, but in gastrinoma it paradoxically causes a rise in gastrin levels.

Treatment Options

Therapy is directed at two goals: controlling acid overproduction and treating the underlying cause (e.g., tumor removal).

Acid‑Suppressive Medications

• Proton pump inhibitors (PPIs) – omeprazole, esomeprazole, pantoprazole, or rabeprazole are first‑line; high‑dose regimens are often required in ZES.
• Histamine‑2 receptor antagonists (H2 blockers) – ranitidine (withdrawn in many markets), famotidine; used as adjuncts or in milder cases.
• Antacids – calcium carbonate or magnesium‑aluminum hydroxide for quick relief, but not sufficient alone for ZES.

Eradication of Helicobacter pylori

If H. pylori infection is present, a 14‑day triple or quadruple therapy (usually a PPI + clarithromycin + amoxicillin/metronidazole ± bismuth) is recommended (CDC, 2023).

Surgical Management

• Localized gastrinoma resection – pancreaticoduodenectomy or enucleation, depending on tumor size and location.
• Metastatic disease – liver-directed therapies (resection, radiofrequency ablation) or systemic therapies such as somatostatin analogs (octreotide, lanreotide).
• Curative surgery is achievable in 60‑70 % of patients with non‑metastatic ZES (NIH, 2022).

Adjunctive Therapies

• Somatostatin analogs – inhibit gastrin release; useful when surgery is not feasible.
• Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors.
• Chemotherapy – reserved for high‑grade, aggressive disease.

Lifestyle & Home Measures

• Avoid trigger foods: caffeine, chocolate, citrus, spicy or fatty meals.
• Eat smaller, more frequent meals rather than large meals.
• Maintain an upright position for at least 2 hours after eating.
• Quit smoking and limit alcohol intake (both increase acid secretion).
• Weight management – excess abdominal fat can worsen reflux and ulcer risk.

Prevention Tips

While you cannot prevent a gastrinoma, many of the more common causes of Zollinger‑Ellison‑type burning are modifiable:

• Test and treat H. pylori if you have a history of ulcers or dyspepsia.
• Use NSAIDs and aspirin sparingly; consider acetaminophen for pain relief when appropriate.
• Apply protective gastric agents (e.g., low‑dose PPIs) if you must take NSAIDs long‑term.
• Adopt a balanced diet rich in fruits, vegetables, and whole grains; limit processed and fried foods.
• Manage stress through regular exercise, mindfulness, or counseling, as stress can exacerbate acid production.
• Schedule regular medical check‑ups if you have a personal or family history of neuroendocrine tumors.

Emergency Warning Signs

Key Take‑aways

Zollinger‑Ellison‑type epigastric burning is a signal that the stomach is producing too much acid, most often due to a gastrinoma but also because of common conditions like peptic ulcer disease, H. pylori infection, or chronic NSAID use. Early recognition, appropriate testing, and targeted treatment—especially high‑dose PPIs and, when indicated, surgical removal of a gastrinoma—can prevent complications such as bleeding, perforation, and malignancy.

Always discuss persistent or severe burning sensations with a healthcare professional, and remember that red‑flag symptoms require urgent evaluation.

---

References (selected):

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023.
• American College of Gastroenterology. “Management of Peptic Ulcer Disease.” 2022 guideline.
• CDC. “Helicobacter pylori infection.” 2023.
• National Institutes of Health (NIH). “Neuroendocrine Tumors Fact Sheet.” 2022.
• Cleveland Clinic. “Proton Pump Inhibitors: Uses and Risks.” 2024.
• World Health Organization. “Classification of Tumours of the Digestive System.” 2021.

```